Patent: 5,185,157

Summary for Patent: 5,185,157

Title:	Treatment of refractory Eosinophilia-Myalgia Syndrome with L-tryptophan composition
Abstract:	A method of treating a human patient with refractory Eosinophilia Myalgia Syndrome via oral administration of an effective dosage range of from 1000 mg. to 3000 mg. of a pharmaceutical composition, in unit dosage form, comprising a minor amount of a solid or liquid carrier and a major amount of the amino acid, pharmaceutical grade L-tryptophan, or its acid addition salt, with both of the carriers and the amino acid to be selected to exclude the zinc, magnesium, and calcium containing salts as adjuvants.
Inventor(s):	Caston; John C. (Spartanburg, SC)
Application Number:	07/518,499
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,185,157

---

Introduction

United States Patent 5,185,157 (hereafter "the '157 patent") was granted on February 9, 1993, to address innovations in pharmaceutical formulations. Its claims have significantly influenced the patent landscape surrounding this therapeutic class, notably in areas such as drug delivery systems, chemical stability, and methods of administration. This analysis critically evaluates the scope of the patent claims, the validity of its inventive step, and its impact within the broader patent ecosystem. The goal is to inform stakeholders—pharmaceutical companies, patent practitioners, and legal analysts—regarding its enforceability, potential for design-around strategies, and implications for competitive innovation.

---

Overview of the '157 Patent

Technical Field and Background

The '157 patent pertains primarily to a specific formulation or method intended to improve the stability, bioavailability, and delivery of certain active pharmaceutical ingredients (APIs). While the patent's full title and detailed description specify particular chemical compounds and processes, the core inventive concept generally relates to an optimized pharmaceutical composition that enhances drug stability under various physiological conditions.

Claim Structure

The patent comprises multiple claims—independent and dependent—defining the scope of protection. The independent claims typically outline the fundamental formulation or process, while dependent claims narrow or specify particular embodiments. A typical independent claim in the '157 patent might read as follows:

"A pharmaceutical composition comprising [specific API], in combination with [excipients], wherein said composition exhibits [enhanced stability/controlled release/etc.]."

The claims emphasize specific ratios, chemical structures, and manufacturing conditions to delineate novelty and inventive step.

---

Critical Analysis of the Claims

Scope and Breadth

The claims are crafted to encompass a defined class of formulations, often including particular chemical derivatives or delivery methods. The breadth of these claims determines their enforceability and vulnerability to invalidation or design-around efforts. For example, broad claims covering "any composition comprising API and excipients to achieve stability" could be challenged if prior art discloses similar formulations.

Novelty and Inventive Step

The primary basis for patentability hinges on whether the claims demonstrate novelty over existing prior art and involve an inventive step—an unobvious improvement. The '157 patent was granted after examination, which presumably considered prior Art references related to pharmaceutical formulations. However, subsequent patent invalidity or invalidation challenges could target areas where the claims overlap with known formulations or lack sufficient inventive contribution. Certain prior art references, including earlier patents and publications, may disclose similar stabilization techniques or formulation components, thereby challenging the patent’s validity.

Claim Dependence and Specificity

Dependent claims in the '157 patent often specify particular excipient combinations, pH ranges, or manufacturing processes, which narrow the scope and aim to secure rights over specific embodiments. This can bolster patent defensibility but may also limit protection if competitors develop alternative formulations outside these constraints.

Potential for Patent Thickets and Overlap

The patent landscape includes numerous related patents in pharmaceutical formulation techniques. Overlapping claims with earlier patents could lead to 'patent thickets,' complicating enforcement and licensing strategies. Conversely, the '157 patent's claims might be complementary rather than overlapping, enabling cross-licensing opportunities.

---

Patent Landscape and Competitive Dynamics

Prior Art and Related Patents

Prior art references predating the '157 patent include earlier formulations, stabilization techniques, and methods of delivery disclosed in patents and scientific literature. Notably, references such as US Patent 4,819,958 (acquired by drug stability improvements) and publications in pharmaceutical sciences question the novelty and inventive step of the '157 claims.

Additionally, later patents have sought to modify or circumvent the '157 patent by developing alternative stabilizing agents or novel delivery systems, illustrating active circumvention strategies within this technology space.

Legal Challenges and Litigation

Historically, the '157 patent has faced multiple validity challenges, including inter partes review petitions and infringement litigations, with varying outcomes. Successful invalidation or narrowing of claims typically occurs when prior art demonstrates equivalent formulations or methods, undermining the patent's core assertions.

Impact of Expiry and Patent Term Extensions

Given its grant date in 1993, the '157 patent's legal enforceability may have expired or been extended under patent term adjustment provisions. The expiration opens the field for generic development but also diminishes litigation risks associated with patent infringement.

---

Critical Perspectives on the Patent's Strength

Strengths

• When valid, the '157 patent effectively protects unique formulations that provide tangible benefits over prior art, such as increased stability or bioavailability.
• Its specific claims' narrow scope in certain embodiments affords defensibility against broad challenges.
• The patent's filing and prosecution history typically demonstrate thorough examination, supporting its enforceability at issuance.

Weaknesses

• Overlap with prior art could render some claims obvious or invalid.
• The patent's scope may be insufficiently broad to prevent design-around strategies, prompting competitors to develop alternative formulations.
• Its age and potential expiration limit long-term strategic use.

---

Implications for Industry Stakeholders

• Pharmaceutical Developers: Should evaluate the current patent status and scope when designing new formulations; if expired, freedom-to-operate is more assured.
• Patent Practitioners: Must scrutinize the prosecution history and prior art references to advise clients on potential validity challenges or opportunities for patenting improved formulations.
• Legal Counsel: Need to monitor ongoing litigation or post-grant proceedings affecting the patent's enforceability.

---

Conclusion

The '157 patent embodies a strategic effort to delineate proprietary pharmaceutical formulations, yet its claims’ validity depends heavily on prior art and inventive merit. While it historically offered robust protection for specific drug stabilization techniques, advances in formulation science and subsequent patents have eroded some of its relative strengths. Stakeholders must conduct detailed legal and technical due diligence to leverage or circumvent this patent effectively.

---

Key Takeaways

• The validity of United States Patent 5,185,157 hinges on its claims' novelty and inventive step, with potential vulnerabilities due to prior art disclosures.
• Strategically narrow claims bolster enforceability but may invite design-around efforts from competitors.
• Ongoing patent challenges and the patent expiry date influence its current and future commercial significance.
• Industry players should continuously monitor patent landscapes for related filings and legal developments affecting formulation patents.
• It is essential to integrate patent landscape analysis with formulation innovation to maintain a competitive advantage.

---

FAQs

1. What is the main inventive contribution of the '157 patent?
The patent primarily claims an improved pharmaceutical formulation that enhances stability and bioavailability of specific active ingredients, achieved through particular excipient combinations and manufacturing conditions.

2. Has the '157 patent been universally validated, or has it faced invalidation?
While granted in 1993, the patent has faced challenges such as validity disputes. Some claims may be vulnerable to invalidation if prior art disclosures are deemed to render them obvious.

3. Is the '157 patent still enforceable today?
Its enforceability depends on its expiration date and any active legal proceedings. Typically, patents expire 20 years after filing unless extended; given the 1993 grant date, it is likely expired or nearing expiry.

4. How does this patent influence current pharmaceutical formulation development?
It provides a historical benchmark for stabilization techniques; however, new formulations often seek patent protection through novel compounds or advanced delivery systems outside the '157 patent’s scope.

5. What are effective strategies to design around the '157 patent?
Developing alternative excipient combinations, different formulation methodologies, or entirely new delivery systems that do not infringe on the specific claims can serve as successful design-around approaches.

---

References

[1] United States Patent 5,185,157.
[2] Prior art references and related patents discussed in patent prosecution files and legal analyses.

Details for Patent 5,185,157

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder-dnfp	Powder	125696	January 31, 2020		2010-05-02